INB03 and XPRO1595 are identical products.  INB03 is the name for our oncology pipeline.

2018

    53. Translational control of depression-like behavior via phosphorylation of eukaryotic translation initiation factor 4E. Aguilar-Valles A, Haji N, De Gregorio D, Matta-Camacho E, Eslamizade MJ, Popic J, Sharma V, Cao R, Rummel C, Tanti A, Wiebe S, Nuñez N, Comai S, Nadon R, Luheshi G, Mechawar N, Turecki G, Lacaille JC, Gobbi G, Sonenberg N. Nat Commun. 2018 Jun 25;9(1):2459. doi: 10.1038/s41467-018-04883-5. Pubmed Link (PDF)
    52. Soluble TNFα signaling within the spinal cord contributes to the development of autonomic dysreflexia and ensuing vascular and immune dysfunction after spinal cord injury. Mironets E, Osei-Owusu P, Bracchi-Ricard V, Fischer R, Owens EA, Ricard J, Wu D, Saltos T, Collyer E, Hou S, Bethea JR, Tom VJ. J Neurosci. 2018 Apr 2. pii: 2376-17. doi: 10.1523/JNEUROSCI.2376-17.2018. [Epub ahead of print]. Pubmed Link (PDF)
    51. Involvement of mGluR I in EphB/ephrinB reverse signaling activation induced retinal ganglion cell apoptosis in a rat chronic hypertension model. Zhao Y, Li Q, Li XY, Cui P, Gao F, Zhu K, Li LZ, Sun XH, Wang Z. Brain Res. 2018 Jan 20. pii: S0006-8993(18)30031-3. doi: 10.1016/j.brainres.2018.01.017. [Epub ahead of print]. Pubmed Link (PDF)

2017

    50. Inhibition of TNF reduces mechanical orofacial hyperalgesia induced by Complete Freund's Adjuvant by a TRPV1-dependent mechanism in mice. Lis K, Grygorowicz T, Cudna A, Szymkowski DE, Bałkowiec-Iskra E. Pharmacol Rep. 2017 Dec;69(6):1380-1385. doi: 10.1016/j.pharep.2017.05.013. Epub 2017 Jun 3. Pubmed Link (PDF)
    49. Systemic TNF-α produces acute cognitive dysfunction and exaggerated sickness behavior when superimposed upon progressive neurodegeneration. Hennessy E, Gormley S, Lopez-Rodriguez AB, Murray C, Murray C, Cunningham C. Brain Behav Immun. 2017 Jan;59:233-244. doi: 10.1016/j.bbi.2016.09.011. Epub 2016 Sep 12. Pubmed Link (PDF)
    48. Hippocampal TNFα Signaling Contributes to Seizure Generation in an Infection-Induced Mouse Model of Limbic Epilepsy. Patel DC, Wallis G, Dahle EJ, McElroy PB, Thomson KE, Tesi RJ, Szymkowski DE, West PJ, Smeal RM, Patel M, Fujinami RS, White HS, Wilcox KS. eNeuro. 2017 May 9;4(2). pii: ENEURO.0105-17.2017. doi: 10.1523/ENEURO.0105-17.2017. eCollection 2017 Mar-Apr. Pubmed Link (PDF)
    47. Therapeutic inhibition of soluble brain TNF promotes remyelination by increasing myelin phagocytosis by microglia. Karamita M, Barnum C, Möbius W, Tansey MG, Szymkowski DE, Lassmann H, Probert L. JCI Insight. 2017 Apr 20;2(8). pii: 87455. doi: 10.1172/jci.insight.87455 Pubmed Link (PDF)
    46. Peripheral administration of the soluble TNF inhibitor XPro1595 modifies brain immune cell profiles, decreases beta-amyloid plaque load, and rescues impaired long-term potentiation in 5xFAD mice. MacPherson KP, Sompol P, Kannarkat GT, Chang J, Sniffen L, Wildner ME, Norris CM, Tansey MG. Neurobiol Dis. 2017 Jun;102:81-95. doi: 10.1016/j.nbd.2017.02.010. Epub 2017 Feb 24. Pubmed Link (PDF)
    45. Toll-like Receptor 4 Mediates Morphine-Induced Neuroinflammation and Tolerance via Soluble Tumor Necrosis Factor Signaling. Eidson LN, Inoue K, Young LJ, Tansey MG, Murphy AZ.Neuropsychopharmacology. 2017 Feb;42(3):661-670. doi: 10.1038/npp.2016.131. Epub 2016 Jul 27. Pubmed Link (PDF)

 2016

    44. Inhibiting tumor necrosis factor-α before amyloidosis prevents synaptic deficits in an Alzheimer's disease model. Cavanagh C, Tse YC, Nguyen HB, Krantic S, Breitner JC, Quirion R, Wong TP. Neurobiol Aging. 2016 Nov;47:41-49. doi: 10.1016/j.neurobiolaging.2016.07.009. Epub 2016 Jul 25. Pubmed Link (PDF)
    43. Genetic Ablation of Soluble TNF Does Not Affect Lesion Size and Functional Recovery after Moderate Spinal Cord Injury in Mice. Ellman DG, Degn M, Lund MC, Clausen BH, Novrup HG, Flæng SB, Jørgensen LH, Suntharalingam L, Svenningsen ÅF, Brambilla R, Lambertsen KL. Mediators Inflamm. 2016;2016:2684098. doi: 10.1155/2016/2684098. Epub 2016 Dec 14. Pubmed Link (PDF)
    42. Oligodendroglial TNFR2 Mediates Membrane TNF-Dependent Repair in Experimental Autoimmune Encephalomyelitis by Promoting Oligodendrocyte Differentiation and Remyelination. Madsen PM, Motti D, Karmally S, Szymkowski DE, Lambertsen KL, Bethea JR, Brambilla R. J Neurosci. 2016 May 4;36(18):5128-43. doi: 10.1523/JNEUROSCI.0211-16.2016. Pubmed Link (PDF)
    41. Inhibition of Soluble Tumor Necrosis Factor Prevents Chemically Induced Carcinogenesis in Mice. Sobo-Vujanovic A, Vujanovic L, DeLeo AB, Concha-Benavente F, Ferris RL, Lin Y, Vujanovic NL. Cancer Immunol Res. 2016 May;4(5):441-51. doi: 10.1158/2326-6066.CIR-15-0104. Epub 2016 Feb 19. Pubmed Link (PDF)
    40. Transmembrane TNF-α is sufficient for articular inflammation and hypernociception in a mouse model of gout. Amaral FA, Bastos LF, Oliveira TH, Dias AC, Oliveira VL, Tavares LD, Costa VV, Galvão I, Soriani FM, Szymkowski DE, Ryffel B, Souza DG, Teixeira MM. Eur J Immunol. 2016 Jan;46(1):204-11. doi: 10.1002/eji.201545798. Epub 2015 Nov 4. Pubmed Link (PDF)

2015 

    39. TNF compromises lysosome acidification and reduces α-synuclein degradation via autophagy in dopaminergic cells. Wang MX, Cheng XY, Jin M, Cao YL, Yang YP, Wang JD, Li Q, Wang F, Hu LF, Liu CF. Exp Neurol. 2015 Sep;271:112-21. doi: 10.1016/j.expneurol.2015.05.008. Epub 2015 May 19. Pubmed Link (PDF)
    38. Soluble Tumor Necrosis Factor Alpha Promotes Retinal Ganglion Cell Death in Glaucoma via Calcium-Permeable AMPA Receptor Activation. Cueva Vargas JL, Osswald IK, Unsain N, Aurousseau MR, Barker PA, Bowie D, Di Polo A. J Neurosci. 2015 Sep 2;35(35):12088-102. doi: 10.1523/JNEUROSCI.1273-15.2015. Pubmed Link (PDF)
    37. Transmembrane TNF-TNFR2 Impairs Th17 Differentiation by Promoting Il2 Expression. Miller PG, Bonn MB, McKarns SC. J Immunol. 2015 Sep 15;195(6):2633-47. doi: 10.4049/jimmunol.1500286. Epub 2015 Aug 12. Pubmed Link (PDF)

2014

    36. Putative role of protein kinase C in neurotoxic inflammation mediated by extracellular heat shock protein 70 after ischemia-reperfusion. Dvoriantchikova G, Santos AR, Saeed AM, Dvoriantchikova X, Ivanov D. J Neuroinflammation. 2014 Apr 23;11:81. doi: 10.1186/1742-2094-11-81. Pubmed Link (PDF)
    35. An adaptive role of TNFα in the regulation of striatal synapses. Lewitus GM, Pribiag H, Duseja R, St-Hilaire M, Stellwagen D. J Neurosci. 2014 Apr 30;34(18):6146-55. doi: 10.1523/JNEUROSCI.3481-13.2014. Pubmed Link (PDF)
    34. AAV-dominant negative tumor necrosis factor (DN-TNF) gene transfer to the striatum does not rescue medium spiny neurons in the YAC128 mouse model of Huntington's disease. Alto LT, Chen X, Ruhn KA, Treviño I, Tansey MG. PLoS One. 2014 May 13;9(5):e96544. doi: 10.1371/journal.pone.0096544. Pubmed Link (PDF)
    33. Dendritic-cell exosomes cross-present Toll-like receptor-ligands and activate bystander dendritic cells. Sobo-Vujanovic A, Munich S, Vujanovic NL. Cell Immunol. 2014 May-Jun;289(1-2):119-27. doi: 10.1016/j.cellimm.2014.03.016. Epub 2014 Apr 8. Pubmed Link (PDF)
    32. Altered expression of oligodendrocyte and neuronal marker genes predicts the clinical onset of autoimmune encephalomyelitis and indicates the effectiveness of multiple sclerosis-directed therapeutics. Evangelidou M, Karamita M, Vamvakas SS, Szymkowski DE, Probert L. J Immunol. 2014 May 1;192(9):4122-33. doi: 10.4049/jimmunol.1300633. Epub 2014 Mar 28. Pubmed Link (PDF)
    31. Adipocyte inflammation is essential for healthy adipose tissue expansion and remodeling. Wernstedt Asterholm I, Tao C, Morley TS, Wang QA, Delgado-Lopez F, Wang ZV, Scherer PE. Cell Metab. 2014 Jul 1;20(1):103-18. doi: 10.1016/j.cmet.2014.05.005. Epub 2014 Jun 12. Pubmed Link (PDF)
    30. Systemically administered anti-TNF therapy ameliorates functional outcomes after focal cerebral ischemia. Clausen BH, Degn M, Martin NA, Couch Y, Karimi L, Ormhøj M, Mortensen ML, Gredal HB, Gardiner C, Sargent II, Szymkowski DE, Petit GH, Deierborg T, Finsen B, Anthony DC, Lambertsen KL. J Neuroinflammation. 2014 Dec 12;11:203. doi: 10.1186/s12974-014-0203-6. Pubmed Link (PDF)
    29. Central but not systemic administration of XPro1595 is therapeutic following moderate spinal cord injury in mice. Novrup HG, Bracchi-Ricard V, Ellman DG, Ricard J, Jain A, Runko E, Lyck L, Yli-Karjanmaa M, Szymkowski DE, Pearse DD, Lambertsen KL, Bethea JR. J Neuroinflammation. 2014 Sep 10;11:159. doi: 10.1186/s12974-014-0159-6. Pubmed Link (PDF)
    28. Peripheral administration of the selective inhibitor of soluble tumor necrosis factor (TNF) XPro®1595 attenuates nigral cell loss and glial activation in 6-OHDA hemiparkinsonian rats. Barnum CJ, Chen X, Chung J, Chang J, Williams M, Grigoryan N, Tesi RJ, Tansey MG. J Parkinsons Dis. 2014;4(3):349-60. doi: 10.3233/JPD-140410. Pubmed Link (PDF)
    27. Selective effects of a therapeutic protein targeting tumor necrosis factor-alpha on cytochrome P450 regulation during infectious colitis: Implications for disease-dependent drug-drug interactions. Nyagode BA, Jahangardi R, Merrell MD, Tansey MG, Morgan ET. Pharmacol Res Perspect. 2014 Feb 1;2(1):e00027. Pubmed Link (PDF)
    26. Inhibition of soluble tumor necrosis factor is therapeutic in Huntington's disease. Hsiao HY, Chiu FL, Chen CM, Wu YR, Chen HM, Chen YC, Kuo HC, Chern Y. Hum Mol Genet. 2014 Aug 15;23(16):4328-44. doi: 10.1093/hmg/ddu151. Epub 2014 Apr 3. Pubmed Link (PDF)
    25. Tumor necrosis factor suppresses NR5A2 activity and intestinal glucocorticoid synthesis to sustain chronic colitis. Huang SC, Lee CT, Chung BC. Sci Signal. 2014 Feb 25;7(314):ra20. doi: 10.1126/scisignal.2004786. Pubmed Link (PDF)

2013

    24. Tumor necrosis factor-neuropeptide Y cross talk regulates inflammation, epithelial barrier functions, and colonic motility. Chandrasekharan B, Jeppsson S, Pienkowski S, Belsham DD, Sitaraman SV, Merlin D, Kokkotou E, Nusrat A, Tansey MG, Srinivasan S. Inflamm Bowel Dis. 2013 Nov;19(12):2535-46. doi: 10.1097/01.MIB.0000437042.59208.9f. Pubmed Link (PDF)
    23. Chronic dim light at night provokes reversible depression-like phenotype: possible role for TNF. Bedrosian TA, Weil ZM, Nelson RJ. Mol Psychiatry. 2013 Aug;18(8):930-6. doi: 10.1038/mp.2012.96. Epub 2012 Jul 24. Pubmed Link (PDF)
    22. Neutralization of membrane TNF, but not soluble TNF, is crucial for the treatment of experimental colitis. Perrier C, de Hertogh G, Cremer J, Vermeire S, Rutgeerts P, Van Assche G, Szymkowski DE, Ceuppens JL. Inflamm Bowel Dis. 2013 Feb;19(2):246-53. doi: 10.1002/ibd.23023. Pubmed Link (PDF)
    21. Peripheral elevation of TNF-α leads to early synaptic abnormalities in the mouse somatosensory cortex in experimental autoimmune encephalomyelitis. Yang G, Parkhurst CN, Hayes S, Gan WB. Proc Natl Acad Sci U S A. 2013 Jun 18;110(25):10306-11. doi: 10.1073/pnas.1222895110. Pubmed Link (PDF)
    20. Differential expression and tumor necrosis factor-mediated regulation of TNFRSF11b/osteoprotegerin production by human melanomas. Oliver JL, Alexander MP, Norrod AG, Mullins IM, Mullins DW. Pigment Cell Melanoma Res. 2013 Jul;26(4):571-9. doi: 10.1111/pcmr.12091. Pubmed Link (PDF)

2012

    19. Inhibition of soluble tumor necrosis factor ameliorates synaptic alterations and Ca2+ dysregulation in aged rats. Sama DM, Mohmmad Abdul H, Furman JL, Artiushin IA, Szymkowski DE, Scheff SW, Norris CM. PLoS One. 2012;7(5):e38170. doi: 10.1371/journal.pone.0038170. Pubmed Link (PDF)
    18. Tumour necrosis factor-mediated macrophage activation in the target organ is critical for clinical manifestation of uveitis. Khera TK, Copland DA, Boldison J, Lait PJ, Szymkowski DE, Dick AD, Nicholson LB. Clin Exp Immunol. 2012 May;168(2):165-77. doi: 10.1111/j.1365-2249.2012.04567.x. Pubmed Link (PDF)
    17. Dendritic cell exosomes directly kill tumor cells and activate natural killer cells via TNF superfamily ligands. Munich S, Sobo-Vujanovic A, Buchser WJ, Beer-Stolz D, Vujanovic NL. Oncoimmunology. 2012 Oct 1;1(7):1074-1083. Pubmed Link (PDF)

2011

    16. Inhibition of soluble tumour necrosis factor is therapeutic in experimental autoimmune encephalomyelitis and promotes axon preservation and remyelination. Brambilla R, Ashbaugh JJ, Magliozzi R, Dellarole A, Karmally S, Szymkowski DE, Bethea JR. Brain. 2011 Sep;134(Pt 9):2736-54. doi: 10.1093/brain/awr199. Pubmed Link (PDF)
    15. Allergic lung inflammation is mediated by soluble tumor necrosis factor (TNF) and attenuated by dominant-negative TNF biologics. Maillet I, Schnyder-Candrian S, Couillin I, Quesniaux VF, Erard F, Moser R, Fleury S, Kanda A, Dombrowicz D, Szymkowski DE, Ryffel B. Am J Respir Cell Mol Biol. 2011 Oct;45(4):731-9. doi: 10.1165/rcmb.2010-0512OC. Pubmed Link (PDF)
    14. Transmembrane tumour necrosis factor is neuroprotective and regulates experimental autoimmune encephalomyelitis via neuronal nuclear factor-kappaB. Taoufik E, Tseveleki V, Chu SY, Tselios T, Karin M, Lassmann H, Szymkowski DE, Probert L. Brain. 2011 Sep;134(Pt 9):2722-35. doi: 10.1093/brain/awr203. Pubmed Link (PDF)
    13. Delayed dominant-negative TNF gene therapy halts progressive loss of nigral dopaminergic neurons in a rat model of Parkinson's disease. Harms AS, Barnum CJ, Ruhn KA, Varghese S, Treviño I, Blesch A, Tansey MG. Mol Ther. 2011 Jan;19(1):46-52. doi: 10.1038/mt.2010.217. Pubmed Link (PDF)

2010

    12. zVAD-induced necroptosis in L929 cells depends on autocrine production of TNFα mediated by the PKC-MAPKs-AP-1 pathway. Wu YT, Tan HL, Huang Q, Sun XJ, Zhu X, Shen HM. Cell Death Differ. 2011 Jan;18(1):26-37. doi: 10.1038/cdd.2010.72. Pubmed Link (PDF)
    11. Soluble TNF, but not membrane TNF, is critical in LPS-induced hepatitis. Olleros ML, Vesin D, Fotio AL, Santiago-Raber ML, Tauzin S, Szymkowski DE, Garcia I.J Hepatol. 2010 Dec;53(6):1059-68. doi: 10.1016/j.jhep.2010.05.029. Pubmed Link (PDF)
    10. Virally infected and matured human dendritic cells activate natural killer cells via cooperative activity of plasma membrane-bound TNF and IL-15. Vujanovic L, Szymkowski DE, Alber S, Watkins SC, Vujanovic NL, Butterfield LH. Blood. 2010 Jul 29;116(4):575-83. doi: 10.1182/blood-2009-08-240325. Pubmed Link (PDF)
    8. Novel mutants of human tumor necrosis factor with dominant-negative properties. Shingarova LN, Boldyreva EF, Yakimov SA, Guryanova SV, Dolgikh DA, Nedospasov SA, Kirpichnikov MP. Biochemistry (Mosc). 2010 Dec;75(12):1458-63. Pubmed Link (PDF)

2009

    7. Dominant-negative tumor necrosis factor protects from Mycobacterium bovis Bacillus Calmette Guérin (BCG) and endotoxin-induced liver injury without compromising host immunity to BCG and Mycobacterium tuberculosis. Olleros ML, Vesin D, Lambou AF, Janssens JP, Ryffel B, Rose S, Frémond C, Quesniaux VF, Szymkowski DE, Garcia I. J Infect Dis. 2009 Apr 1;199(7):1053-63. doi: 10.1086/597204. Pubmed Link (PDF)
    6. Inhibition of soluble TNF signaling in a mouse model of Alzheimer's disease prevents pre-plaque amyloid-associated neuropathology. McAlpine FE, Lee JK, Harms AS, Ruhn KA, Blurton-Jones M, Hong J, Das P, Golde TE, LaFerla FM, Oddo S, Blesch A, Tansey MG. Neurobiol Dis. 2009 Apr;34(1):163-77. Pubmed Link (PDF)
    5. Intranigral lentiviral delivery of dominant-negative TNF attenuates neurodegeneration and behavioral deficits in hemiparkinsonian rats. McCoy MK, Ruhn KA, Martinez TN, McAlpine FE, Blesch A, Tansey MG. Mol Ther. 2008 Sep;16(9):1572-9. doi: 10.1038/mt.2008.146. Pubmed Link (PDF)

2007

    4. Dominant-negative inhibitors of soluble TNF attenuate experimental arthritis without suppressing innate immunity to infection. Zalevsky J, Secher T, Ezhevsky SA, Janot L, Steed PM, O'Brien C, Eivazi A, Kung J, Nguyen DH, Doberstein SK, Erard F, Ryffel B, Szymkowski DE. J Immunol. 2007 Aug 1;179(3):1872-83. Pubmed Link (PDF)

2006

    3. Blocking soluble tumor necrosis factor signaling with dominant-negative tumor necrosis factor inhibitor attenuates loss of dopaminergic neurons in models of Parkinson's disease. McCoy MK, Martinez TN, Ruhn KA, Szymkowski DE, Smith CG, Botterman BR, Tansey KE, Tansey MG. J Neurosci. 2006 Sep 13;26(37):9365-75. Pubmed Link (PDF)

2005

    2. JNK and tumor necrosis factor-alpha mediate free fatty acid-induced insulin resistance in 3T3-L1 adipocytes. Nguyen MT, Satoh H, Favelyukis S, Babendure JL, Imamura T, Sbodio JI, Zalevsky J, Dahiyat BI, Chi NW, Olefsky JM. J Biol Chem. 2005 Oct 21;280(42):35361-71. Pubmed Link (PDF)

2003.

    1. Inactivation of TNF signaling by rationally designed dominant-negative TNF variants. Steed PM, Tansey MG, Zalevsky J, Zhukovsky EA, Desjarlais JR, Szymkowski DE, Abbott C, Carmichael D, Chan C, Cherry L, Cheung P, Chirino AJ, Chung HH, Doberstein SK, Eivazi A, Filikov AV, Gao SX, Hubert RS, Hwang M, Hyun L, Kashi S, Kim A, Kim E, Kung J, Martinez SP, Muchhal US, Nguyen DH, O'Brien C, O'Keefe D, Singer K, Vafa O, Vielmetter J, Yoder SC, Dahiyat BI. Science. 2003 Sep 26;301(5641):1895-8. Pubmed Link (PDF)

 

Have a Question?
858 964 3720
Email Us
dmoss@inmunebio.com
Opening Hours
M - F 8am to 5pm PST